CALL FOR ABSTRACTS

AACR-NCI-EORTC INTERNATIONAL CONFERENCE

MOLECULAR TARGETS AND CANCER THERAPEUTICS

DISCOVERY, BIOLOGY, AND CLINICAL APPLICATIONS

THE PREMIER INTERNATIONAL MEETING FEATURING NOVEL CANCER THERAPEUTICS

November 5-9, 2015
John B. Hynes Veterans Memorial Convention Center | Boston, MA

Abstract Submission Deadline: Tuesday, August 4 • Late-Breaking Abstract Submission Deadline: Thursday, September 24
Early Registration Deadline: Monday, August 24 • Advance Registration Deadline: Monday, October 5

Continuing Medical Education Activity-AMA PRA Category 1 Credits™ available

www.AACR.org
MOLECULAR TARGETS AND CANCER THERAPEUTICS

ABOUT THE COVER
2. The morphology of SW480 colorectal cancer cells in response to the treatment with TGFβ for 48 hours have migrated through 8 μm-diameter pores in a Transwell assay. Clin Cancer Res. November 15, 2014:20;5835.
3. The predicted binding model in which tivantinib (ARQ197) binds to the colchicine binding site of tubulin, calculated by GOLD docking program. Mol Cancer Ther. December 2014:13;2978.
4. 2-day-old zebrafish embryo showing developing lymphatic vessels in green (lyve1:egfp) and endothelial cell nuclei in red (kdrl:nls:mcherry). Mol Cancer Ther. October 2014:13;2450.
TABLE OF CONTENTS

Organizing and Scientific Committees................................................................................................................................................... 2
Program Schedule.......................................................................................................................................................................................... 4
Abstract Submission Categories and Guidelines .................................................................................................................................. 10
Late-Breaking Abstract Submission Guidelines .................................................................................................................................... 12
Accommodations and Travel ........................................................................................................................................................................ 14
Continuing Medical Education .................................................................................................................................................................... 16
Financial Support for Attendance .............................................................................................................................................................. 17
Registration ....................................................................................................................................................................................................... 18
General Information ...................................................................................................................................................................................... 20
Press ................................................................................................................................................................................................................... 22
Support Opportunities .................................................................................................................................................................................. 24
Exhibit Information .................................................................................................................................................................................... 25
Webcasts of Sessions .................................................................................................................................................................................... 26
Registration Form .................................................................................................................................................................................................. 27

ABOUT THE CONFERENCE ORGANIZERS

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 101 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 25 conferences and educational workshops, the largest of which is the AACR Annual Meeting with over 19,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.

The National Cancer Institute (NCI), founded in 1937, is the U.S. Federal Government’s principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients.

The European Organization for Research and Treatment of Cancer (EORTC), based in Brussels, Belgium, unites European cancer clinical research experts from all disciplines for trans-national collaboration. It links a network of over 2,500 collaborators from all disciplines involved in cancer treatment and research in more than 300 hospitals in over 30 countries and offers an integrated approach to drug development, drug evaluation programs, and medical practices.
ORGANIZING AND SCIENTIFIC COMMITTEES

ORGANIZING COMMITTEE CO-CHAIRPERSONS:

Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA (AACR)*

James H. Doroshow, MD
National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)*

Roger Stupp, MD
University Hospital Zürich (USZ), Zürich, Switzerland (EORTC)*

SCIENTIFIC COMMITTEE CO-CHAIRPERSONS:

Levi A. Garraway, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA (AACR)*

Lee J. Helman, MD
National Cancer Institute, Bethesda, MD, USA (NCI)*

Jean-Charles Soria, MD, PhD
Institut Gustave-Roussy, Villejuif, France (EORTC)*

SCIENTIFIC COMMITTEE:

Cory Abate-Shen, PhD, Columbia University Irving Comprehensive Cancer Center, New York, NY, USA (AACR)
Jeffrey S. Abrams, MD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Scott A. Armstrong, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (AACR)
Anna D. Barker, PhD, Arizona State University, Scottsdale, AZ, USA (AACR)
John C. Byrd, MD, The Ohio State University, Columbus, OH, USA (AACR)*
Phillippe Cassier, MD, Centre Léon Bérard, Lyon, France (EORTC)
Jenny C. Chang, MD, Houston Methodist Hospital, Houston, TX, USA (AACR)
Rajesh Chopra, MBBS, PhD, Celgene Corporation, Summit, NJ, USA (EORTC)
Karen M. Cichowski, PhD, Brigham & Women’s Hospital, Boston, MA, USA (AACR)
Jerry M. Collins, PhD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Barbara A. Conley, MD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
William L. Dahut, MD, National Cancer Institute, Bethesda, MD, USA (NCI)
Filippo de Braud, MD, Istituto Nazionale dei Tumori, Milan, Italy (EORTC)
James H. Doroshow, MD, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
CALL FOR ABSTRACTS  ■  Abstract Submission Deadline: August 4, 2015

Lori S. Friedman, PhD, Genentech, Inc., South San Francisco, CA, USA (AACR)
James L. Gulley, MD, PhD, National Cancer Institute, Bethesda, MD, USA (NCI)*
Toby Tucker Hecht, PhD, National Cancer Institute, Rockville, MD, USA (NCI)
Lee J. Helman, MD, National Cancer Institute, Bethesda, MD, USA (NCI)
Manuel Hidalgo, MD, PhD, Centro Nacional de Investigaciones Oncolégicas (CNIO), Madrid, Spain (EORTC)
Patrick Hwu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Antoine Italiano, MD, Institut Bergonié, Bordeaux, France (EORTC)*
S. Percy Ivy, MD, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Paula M. Jacobs, PhD, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Ulrik Lassen, PhD, Rigshospitalet, Copenhagen, Denmark (EORTC)
Jose A. Lopez-Martin, MD, “12 de Octubre” University Hospital, Madrid, Spain (EORTC)
Patricia M. LoRusso, DO, Yale Cancer Center, New Haven, CT, USA (AACR)
Christophe Massard, MD, Institut Gustave-Roussy, Villejuif, France (EORTC)
Paul S. Meltzer, MD, PhD, National Cancer Institute, Bethesda, MD, USA (AACR)
Franziska Michor, PhD, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
Gordon B. Mills, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Stephen A. Munk, PhD, Ash Stevens Inc., Detroit, MI, USA (AACR)
Ruth Plummer, MA, DPhil, BMBCh, MD, FRCP, Newcastle University, Newcastle Upon Tyne, United Kingdom (EORTC)
Yves G. Pommier, MD, PhD, National Cancer Institute-CCR, Bethesda, MD, USA (NCI)
Eric Raymond, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (EORTC)
Victoria M. Richon, PhD, Sanofi Oncology, Cambridge, MA, USA (AACR)
Jordi Rodon, MD, Vall d’Hebron University Hospital, Barcelona, Spain (EORTC)
Joel P. Schneider, PhD, National Cancer Institute, Frederick, MD, USA (NCI)
Geoffrey I. Shapiro, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
David B. Solit, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (AACR)
Jeffrey A. Sosman, MD, Vanderbilt University Medical Center, Nashville, TN, USA (AACR)
Patricia S. Steeg, PhD, National Cancer Institute, Bethesda, MD, USA (NCI)
Beverly A. Teicher, PhD, National Cancer Institute, Bethesda, MD, USA (NCI)
Craig B. Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (AACR)
Joseph E. Tomaszewski, PhD, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Christopher J. Twelves, MD, St. James Institute of Oncology, West Yorkshire, United Kingdom (EORTC)
Victor E. Velculescu, MD, PhD, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA (AACR)
Emile E. Voest, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands (EORTC)
Roger Von Moos, DMD, Kantonsspital Graubünden, Chur, Switzerland (EORTC)
Thomas E. Yankeelov, PhD, Vanderbilt University Medical Center, Nashville, TN, USA (AACR)
Timothy A. Yap, MD, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom (EORTC)
Antoine Yver, MD, MSc, AstraZeneca, Gaithersburg, MD, USA (AACR)
James A. Zwiebel, MD, National Cancer Institute, Rockville, MD, USA (NCI)*

*member of Executive Committee
THURSDAY, NOVEMBER 5, 2015

Registration
10:00 a.m.-6:30 p.m.

Educational Session 1: Immunotherapy 101
3:00 p.m.-4:30 p.m.
Session Co-Chairpersons: Jolanda de Vries, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands, and Mary L. (Nora) Disis, University of Washington, Seattle, WA, USA

- Title to be announced  
  Jolanda de Vries
- Title to be announced  
  Stephen Gottschalk, Baylor College of Medicine, Houston, TX, USA
- Immune checkpoint inhibitors: Opportunities and challenges  
  Mary L. (Nora) Disis
- Additional speaker to be announced

Educational Session 2: Mutation Profiling / Return of Genetic Data
4:45 p.m.-6:15 p.m.
Session Co-Chairpersons: Lee J. Helman, National Cancer Institute, Bethesda, MD, USA, and Sharon E. Plon, Baylor College of Medicine, Houston, TX, USA

- Title to be announced  
  Lee J. Helman
- National scale cancer sequencing and treatment response data integration in the Netherlands  
  Edwin Cuppen, University Medical Center Utrecht, Utrecht, The Netherlands
- Returning germline results to cancer patients  
  Sharon E. Plon

Opening Networking Reception
6:30 p.m.-8:00 p.m.

FRIDAY, NOVEMBER 6, 2015

Registration
6:30 a.m.-5:30 p.m.

Continental Breakfast
7:00 a.m.-8:00 a.m.

Welcome and Opening Remarks
8:00 a.m.-8:05 a.m.
- Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA ( AACR)
- Lee J. Helman, National Cancer Institute, Bethesda, MD, USA (NCI)
- Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (EORTC)
Keynote Lectures
8:05 a.m.–9:35 a.m.

Updates on engineered T cells as cancer therapies
Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

Impact of gut microbiota in cancer development and therapeutics
Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France

Break
9:35 a.m.–10:00 a.m.

Plenary Session 1: Cellular Immunotherapy
10:00 a.m.–12:00 p.m.
Session Co-Chairpersons: Alexander M.M. Eggermont, Institut Gustave-Roussy, Villejuif, France, and Crystal L. Mackall, National Cancer Institute, Bethesda, MD, USA

Title to be announced
Crystal L. Mackall

Additional speakers to be announced

Exhibit Show
12:00 p.m.–4:00 p.m.

Poster Session A
12:15 p.m.–3:15 p.m.
Concurrent Sessions 1-4
3:30 p.m.-5:30 p.m.

Concurrent Session 1: Radiomics: Imaging in the Context of Drug Development and Personalized Medicine
Session Co-Chairpersons: E.G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands, and Robert J. Gillies, Moffitt Cancer Center & Research Institute, Tampa, FL, USA

- The radiology reading room of the future
  Robert J. Gillies
- Incorporating molecular imaging methods in early drug development
  E.G. Elisabeth de Vries
- Radiogenomics
  Hugo Aerts, Brigham & Women’s Hospital, Boston, MA, USA

Concurrent Session 2: Liquid Biopsies to Monitor Clonal Evolution and Drug Resistance
Session Co-Chairpersons: Alberto Bardelli, IRCC - University of Turin Medical School, Candiolo, Italy, and Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

- Analysis of circulating tumor DNA to monitor clonal evolution
  Muhammed Murtaza, Translational Genomics Research Institute, Phoenix, AZ, USA
- Comprehensive detection of structural alterations in the circulation of cancer patients
  Mark Sausen, Personal Genome Diagnostics, Baltimore, MD, USA
- Heterogeneity, drug resistance, and clonal dynamics in colorectal cancers
  Alberto Bardelli

Concurrent Session 3: Handling Toxicities of Immune Checkpoints/Checkpoint Blockade
Session Co-Chairperson: Antoine Italiano, Institut Bergonié, Bordeaux, France

- Toxicities from CTLA-4 and PD1 immune checkpoint inhibition: An overview
  Antoine Italiano
- Additional speakers to be announced

Concurrent Session 4: Therapeutic Vaccines
Session Co-Chairpersons: James L. Gulley, National Cancer Institute, Bethesda, MD, USA, and Daniel E. Speiser, Ludwig Cancer Research Center/University of Lausanne, Laussane, Switzerland

- Introduction
  James L. Gulley
- Targeting epithelial-mesenchymal transition via brachyury-based cancer vaccines
  Claudia M. Palena, National Cancer Institute-CCR, Bethesda, MD, USA
- Developing personalized neoantigen-based cancer vaccines
  Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA, USA
- DNA vaccines as treatment for prostate cancer
  Douglas G. McNeel, University of Wisconsin-Madison, Madison, WI, USA

Closing remarks
Daniel E. Speiser

SATURDAY, NOVEMBER 7, 2015

Registration
7:00 a.m.-5:30 p.m.

Continental Breakfast
7:00 a.m.-8:00 a.m.

Plenary Session 2: Immunotherapy Checkpoints
8:00 a.m.-10:00 a.m.
Session Co-Chairperson: Paola A. Ascierto, Istituto Nazionale Tumori, Naples, Italy

- Title to be announced
  Paola A. Ascierto
- Additional speakers to be announced
Break
10:00 a.m.-10:20 a.m.

Plenary Session 3: Update on Targeting RAS and Cancer
10:20 a.m.-12:20 p.m.
Session Co-Chairpersons: Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain, and Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Targeting the MAPK cascade in K-RAS driven cancer
Mariano Barbacid

Nontraditional chemical approaches to directly target K-RAS
Kevan M. Shokat, University of California/Howard Hughes Medical Institute, San Francisco, CA, USA

KRAS dependency in pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Targeting K-RAS stemness
Frank McCormick

Poster Session B
12:30 p.m.-3:30 p.m.

Exhibit Show
12:30 p.m.-4:00 p.m.

Concurrent Sessions 5-8
3:45 p.m.-5:45 p.m.

Concurrent Session 5: Systems Biology
Session Co-Chairpersons: Trey Ideker, University of California, San Diego, CA, USA, and Walter Kolch, Systems Biology Ireland, Dublin, Ireland

The Cancer Cell Map Initiative: Mapping molecular networks for tumor stratification and treatment
Trey Ideker

From the cancer landscape to personalized treatment
Lodewyk F. Wessels, Netherlands Cancer Institute, Amsterdam, The Netherlands

Personalized cancer diagnostics and therapeutics based on the computational modeling of signal transduction networks
Walter Kolch

Concurrent Session 6: Advances in Targeting the Hormone Axis
Session Co-Chairpersons: Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom, and Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Resistance mechanisms subverting the AR program in CRPC: Opportunities for new therapeutics
Peter S. Nelson

Title to be announced
Johann S. de Bono

Additional speaker to be announced

Concurrent Session 7: Analysis of Single Cells
Session Co-Chairpersons: Caroline Dive, CRUK Manchester Institute, Manchester, United Kingdom, and Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA

Using CTCs to improve outcomes in SCLC: Single cell profiling, ex vivo cultures, and mouse models
Caroline Dive

Fluid biopsy in prostate cancer, from biochemical relapse to castrate resistance
Peter Kuhn, University of Southern California, Los Angeles, CA, USA

Microfluidic isolation and molecular analysis of single CTCs
Daniel A. Haber
Concurrent Session 8: Cancer Epigenetics and Metabolism
Session Co-Chairpersons: Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, and Roger Stupp, University Hospital Zürich, Zürich, Switzerland
   Epigenetic therapies for TET/IDH-mutant leukemias
   Ross L. Levine
   Additional speakers to be announced

SUNDAY, NOVEMBER 8, 2015

Registration
7:00 a.m.-5:30 p.m.

Continental Breakfast
7:00 a.m.-8:00 a.m.

Plenary Session 4: Advances in Targeted Therapy
8:00 a.m.-10:00 a.m.
Session Co-Chairpersons: José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, USA, and Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain
   Speakers to be announced

Break
10:00 a.m.-10:20 a.m.

Plenary Session 5: Advances in Targeted DNA Repair
10:20 a.m.-12:20 p.m.
Session Co-Chairpersons: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA, USA, and Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France
   ERCC1 alternative read outs
   Jean-Charles Soria
   POLQ and PARP inhibitor
   Alan D. D’Andrea
   Exploiting oncogene-induced DNA damage as a vulnerability to treat cancer: ATR inhibitors
   Oscar Fernandez-Capetillo, Spanish National Cancer Research Center, Madrid, Spain
   PARP trapping versus PARP catalytic inhibition and coupling with TDP1
   Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA

Poster Session C
12:30 p.m.-3:30 p.m.

Exhibit Show
12:30 p.m.-4:00 p.m.
Plenary Session 6: Resistance to Targeted Therapy  
3:45 p.m.-5:45 p.m.  
Session Co-Chairpersons: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA, and Richard M. Marais, Cancer Research UK Manchester Institute, Manchester, United Kingdom

- Title to be announced  
  Levi A. Garraway  

- Mechanisms of resistance of targeted therapies in leukemia  
  John C. Byrd, The Ohio State University Wexner Medical Center, Columbus, OH, USA  
  Title to be announced  
  Richard M. Marais  

- Additional speaker to be announced

MONDAY, NOVEMBER 9, 2015

Registration  
7:00 a.m.-12:00 p.m.

Continental Breakfast  
7:00 a.m.-8:00 a.m.

Plenary Session 7: Tumor Microenvironment  
8:00 a.m.-10:00 a.m.  
Session Co-Chairpersons: Marina Y. Konopleva, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Christophe Massard, Institut Gustave-Roussy, Villejuif, France

- Altered metabolism in leukemic microenvironment  
  Marina Y. Konopleva  

- The multifaceted role of Notch signaling in tumor/microenvironment interaction  
  Jon C. Aster, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, USA  

- Notch inhibitors in clinic  
  Christophe Massard  

- Additional speaker to be announced

Break  
10:00 a.m.-10:20 a.m.

Plenary Session 8: The In Vitro Patient  
10:20 a.m.-12:20 p.m.  
Session Co-Chairpersons: James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA, and Emile E. Voest, Netherlands Cancer Institute, Amsterdam, The Netherlands

- Use of tumor organoids in personalized medicine  
  Emile E. Voest  
  Title to be announced  
  James H. Doroshow  

- Ovarian PDX models: Of mice and (wo)men...and personalized treatment  
  Paul Halvaska, Merck Research Laboratories, Rahway, NJ, USA  

- High-throughput drug screens in cancer cell models to enable precision cancer medicine  
  Matthew Garnett, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Closing Remarks/Adjourn  
12:20 p.m.-12:30 p.m.
When submitting an abstract for the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the Online Abstract Submission System, authors will be asked to choose the appropriate category below that best describes the scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their review of abstracts. Before making a selection, authors should review the entire list for the most appropriate abstract category.

**Angiogenesis and antiangiogenesis agents**

**Animal models**

**Apoptosis, necrosis, and autophagy**

**Bioinformatics**

**Biomarkers**

**Cancer stem cells**

**Cell cycle regulators**

**Cellular responses to therapy**

**Chemistry**

**Chemoprevention**

**Clinical trials**

**Differentiation**

**DNA repair and modulation**

**Drug delivery**

**Drug design**

**Drug metabolism, transport, and biodistribution**

**Drug resistance and modifiers**

**Drug screening**

**EGFR/Her2**

**Epigenetic regulation of tumor immunity**

**Epigenetic targets**

**Gene therapies**

**Genomics, proteomics, and target discovery**

**Heat shock proteins**

**Hormonal agents and therapy**

**Imaging**

**Immune checkpoints**

**Immune mechanisms invoked by radiation therapy**

**Immune modulators**

**Immune monitoring/clinical correlates**

**Immune response to therapies**

**In vitro and in vivo models for targets**

**MAPK pathways**

**Metabolism**

**Metastasis and invasion**

**Molecular classification of tumors**

**Monoclonal antibodies**

**mTOR/PI3-Kinase**

**Natural products**

**New molecular targets**

**Novel assay technology**

**Pediatric early drug development**

**Pharmacogenetics, pharmacogenomics, and therapeutic response**

**Pharmacokinetics and pharmacodynamics**

**Protein-protein interaction**

**Radiotherapeutics**

**RNA and RNA-based technologies and therapies**

**Signal transduction modulators**

**Target identification and validation**

**Therapeutic agents: Biological**

**Therapeutic agents: Small molecule kinase inhibitors**

**Therapeutic agents: Other**

**Topoisomerase inhibitors**

**Toxicology**

**Tubulin-interacting agents**

**Tumor immunology targets**

**Tumor microenvironment**

**Tumor suppressors**
Guidelines for Preparation and Submission of Abstracts
(Submission deadline: 11:59 p.m. U.S. Eastern Time, Tuesday, August 4, 2015)

Authors must submit abstracts for presentation at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the AACR Online Abstract Submission System, which will be available at www.AACR.org/Targets15 beginning Monday, June 15, 2015. You can create, modify, and submit abstracts until the Tuesday, August 4, 2015, submission deadline. Complete instructions on the use of the AACR Online Abstract Submission System will be provided online.

While the online abstract submitter has been optimized for the current versions of most browsers, Safari version 3.2 or higher is recommended for Mac users and Microsoft Internet Explorer version 8.0 or higher is recommended for Windows users. Users of IE 8.0 or 9.0 must display the online submitter in Compatibility View. (From the Command Bar, select Tools, and then select the “Compatibility View settings” option. Enter abstractsonline.com into the window, click the “Add” button, and then click the “Close” button.)

Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or support@abstractsonline.com.

Content of Abstracts
Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.

Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout the abstract. For more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).

Copyright Transfer/Abstract Presentation
On behalf of all authors, the corresponding author must:

1. Transfer copyright of the abstract to the AACR for publication
2. Confirm that an author will register to attend the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference and present the abstract.

NEW IN 2015!

Late-Breaking Abstract Submission
Abstracts that contain new data (unavailable at the time of the August 4 regular submission deadline) may be submitted as a late-breaking abstract beginning on Tuesday, September 15, 2015. Submissions must be completed by Thursday, September 24, 2015. Late-breaking abstracts will be considered for both oral and poster presentations.

Expanded Opportunities for Short Talks
A subcommittee of the Scientific Committee will evaluate highly rated regular and late-breaking abstracts and where thematically appropriate, invite authors to present a short talk in one of the eight Concurrent Sessions in the program. All accepted abstracts are eligible. Not all sessions will include short talks.

Release Date for Abstracts
All accepted abstracts are scheduled to be posted online via the conference itinerary planner on Monday, October 26, 2015 (with the exception of those abstracts selected for inclusion in the AACR press program). Abstracts will not be available before this date.
Abstract Control Number
An abstract control number (e.g., 15-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the abstract control number in any abstract communications.

Financial Relationships of Co-Authors
Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of all of your co-authors. For more information on financial relationships, visit www.AACR.org/CME.

Length of Abstracts
The combined length of the abstract body, title, and tables may not exceed 3,000 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

Disclosure of Chemical Structures
At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules.

If chemical compounds were used, the submitting author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, indication of the intent to disclose any such structures at the time of presentation is required.

The Scientific Committee will evaluate the information provided by the submitting author and determine the acceptability of the abstract for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient scientific merit.

Submission Deadline
The deadline for abstract submissions is 11:59 p.m. U.S. Eastern Time, Tuesday, August 4, 2015. Abstracts submitted in any form after the deadline will not be considered by the Scientific Committee. No changes may be made in abstracts after the August 4, 2015, deadline.

Guidelines for Preparation and Submission of Late-Breaking Abstracts

Late-Breaking Abstract Submission Process
Abstracts detailing highly significant and timely findings in any area of molecular targets and cancer therapeutics that were not available at the time of the regular abstract deadline will be considered for both oral and poster presentation at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. Only those abstracts that are deemed to be of high scientific priority will be accepted. All stakeholders, including members of industry, are encouraged to submit late-breaking abstracts.

Late-breaking abstract submission will open on Tuesday, September 15, 2015 and close at 11:59 p.m. U.S. Eastern Time on Thursday, September 24, 2015. Late-breaking abstracts must be submitted using the AACR Online Abstract Submission System, which will be available at www.AACR.org/Targets15 over these dates only.

A special subcommittee of the Scientific Committee will evaluate the merit of late-breaking abstracts.
Deadline for Withdrawal of Abstracts

The AACR cannot comply with any request for withdrawal of an abstract that will delay the publication of the Program. However, requests to withdraw abstracts will be accepted through Friday, September 19, 2015. Withdrawal requests must be sent by email to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

Presentation of Abstracts at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Every abstract that has been accepted for publication in the online Proceedings must also be presented at the meeting. Specifically, the author listed as the presenter for an abstract submission must register for the meeting and attend the session in which the abstract is scheduled to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the abstract, he or she must contact the AACR Program Development Department to designate a co-author to serve as the presenter. If no authors are available to present the abstract, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or abstract@aacr.org.

Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

- The withdrawal of the abstract from the session
- The removal of the abstract from the online Proceedings
- The loss of future abstract submission/authorship privileges for the presenter of the abstract

Abstract Release and Publication

With the exception of those abstracts selected for inclusion in the AACR press program, all accepted abstracts are scheduled to be posted online via the conference itinerary planner on Monday, October 26, 2015. Abstracts will not be released earlier than that date. After the conference, the presented abstracts will be published as an online-only supplement to the AACR journal Molecular Cancer Therapeutics.
The conference will be held at the John B. Hynes Veterans Memorial Convention Center, located in the heart of Boston’s historic Back Bay neighborhood and just 5 miles/8 km from Boston’s Logan International Airport. In many ways, the Hynes Convention Center is a city within a city - connected to two major retail complexes that contain just about everything you need during your stay. Fast food, fine dining, sundries, personal services, world-class shopping - all under one roof. Attendees at the 2015 Molecular Targets and Cancer Therapeutics conference can experience a serious slice of Boston without ever worrying about the weather.

The AACR has contracted with several hotels to offer reduced room rates for attendees at this year’s conference. The Sheraton Boston Hotel will serve as the headquarters hotel for the 2015 Molecular Targets and Cancer Therapeutics conference, with the Hilton Boston Back Bay and Marriott Copley Place also serving as official conference hotels. Please review the pricing options below and the map on page 15 before making reservations.

Hotel reservations can be made by phone or online through AACR Housing. AACR Housing will open Monday, June 22, 2015 and accept reservations through Monday, October 5, 2015. After October 5, reservations and rates will be subject to hotel availability. Room reservations must be guaranteed with a major credit card. To make a reservation please visit the Accommodations and Travel webpage at www.AACR.org/Targets15.

<table>
<thead>
<tr>
<th>Map Number</th>
<th>Hotels</th>
<th>Single/Double Rate</th>
<th>Triple/Quad Rate</th>
<th>Smoke-Free Hotel</th>
<th>Business Center</th>
<th>Coffee Maker</th>
<th>High-Speed Internet</th>
<th>Onsite Fitness Center</th>
<th>Indoor/Outdoor Pool</th>
<th>Restaurants</th>
<th>Bars</th>
<th>Room Service</th>
<th>Comp. Breakfast</th>
<th>Self Parking</th>
<th>Valet Parking</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sheraton Boston (Headquarter hotel)</td>
<td>$249/ $249</td>
<td>$289/ $299</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>$9.95 (in guest rooms)</td>
<td>No Charge</td>
<td>Indoor</td>
<td>1</td>
<td>1</td>
<td>24 hours</td>
<td>No</td>
<td>No</td>
<td>$51</td>
</tr>
<tr>
<td>2</td>
<td>Hilton Boston Back Bay</td>
<td>$243/ $243</td>
<td>$263/ $263</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No Charge (in guest rooms)</td>
<td>No Charge</td>
<td>Indoor</td>
<td>1</td>
<td>1</td>
<td>24 hours</td>
<td>No</td>
<td>No</td>
<td>$43</td>
</tr>
<tr>
<td>3</td>
<td>Marriott Copley Place</td>
<td>$245/ $245</td>
<td>$265/ $265</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No Charge (in guest rooms)</td>
<td>No Charge</td>
<td>Indoor</td>
<td>2</td>
<td>2</td>
<td>24 hours</td>
<td>No</td>
<td>No</td>
<td>$53</td>
</tr>
</tbody>
</table>

Room rates are in U.S. Dollars.

For more information on the convention center and conference hotels, please visit www.AACR.org/Targets15 and follow the link for Accommodations and Travel.
Travel to Boston

The closest major airport to the Hynes Convention Center and conference hotels is Boston’s Logan International Airport (BOS), located approximately 5 miles / 8 km (15-20 minutes) from the Hynes Convention Center.

The AACR has named Gant Travel Management as its official travel coordinator for this conference. Gant will provide custom itineraries with the lowest applicable airfares and best journey time. Fly on United Airlines, the official airline of this conference, and save with special discounts exclusive to attendees and guests. Full mileage credit will be earned by frequent flyer club members. To receive the exclusive discounts, please contact Gant toll-free at 877-924-2298 (630-227-3818 if outside of the U.S./Canada) or by email at aacr@ganttravel.com.

Gant is open from 7:30 a.m. to 6:00 p.m. U.S. Central Time, Monday through Friday.

Amtrak train service is also readily available for attendees traveling from the Eastern U.S. to Boston. Amtrak’s Back Bay Station is approximately one mile from the Hynes Convention Center.

For additional information on travel to Boston and ground transportation once you arrive, please visit www.AACR.org/Targets15 and follow the link for Accommodations and Travel.

International Travel

Researchers from more than 50 different countries around the world regularly participate in this joint AACR-NCI-EORTC conference. If you plan to attend the 2015 Molecular Targets and Cancer Therapeutics conference, please contact the American Consulate in your country to review the current regulations for travel to the United States. Obtaining the proper documentation may take several weeks or months, depending on your location, so please contact the consulate as soon as possible if you are considering attending this conference. Information is also available on the U.S. Department of State website at www.travel.state.gov.
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Full Accreditation status from the Accreditation Council for Continuing Medical Education (ACCME). The CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advance the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.

Continuing Medical Education Activity—AMA PRA Category 1 Credits™ will be available. Details will be available online at www.AACR.org/Targets15.
FINANCIAL SUPPORT FOR ATTENDANCE

AACR Scholar-in-Training Awards
AACR Associate members in good standing who submit abstracts may be considered for a Scholar-in-Training Award to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The number of awards provided and the dollar amounts of each award will be based on available funding. The award application deadline is **Tuesday, August 4, 2015**. Additional information, abstract submission, and application instructions are available online at [www.AACR.org/Targets15](http://www.AACR.org/Targets15).

AACR Minority-Serving Institution (MSI) Faculty Scholar in Cancer Research Awards
The AACR offers awards in cancer research for participation in its meetings and conferences to full-time faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who are scientists at the Assistant Professor level or above. The AACR MSI Faculty Scholar Awards program is supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute. The purposes of the awards are to increase the scientific knowledge base of faculty members at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. The award application deadline is **Tuesday, August 4, 2015**. Additional information and application instructions are available online at [www.AACR.org/Targets15](http://www.AACR.org/Targets15).

AACR Minority Scholar in Cancer Research Awards
The AACR is pleased to administer this important award program that is supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute (NCI) and provides funds for the participation of meritorious minority scientists in AACR meetings and conferences. These awards are intended to enhance the education and training of minority researchers and to increase the visibility and recognition of minorities involved in cancer research. Eligible scientists are full-time predoctoral (graduate or medical) students or residents, clinical or postdoctoral fellows, and junior faculty who are either engaged in cancer research or who have the training and potential to make contributions to this field. This program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research. These groups are African American/Black, Alaska Native, Hispanic American, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is **Tuesday, August 4, 2015**. Additional information and application instructions are available online at [www.AACR.org/Targets15](http://www.AACR.org/Targets15).

AACR Women in Cancer Research Scholar Awards
Women in Cancer Research (WICR) Scholar Awards are awarded to AACR-WICR members in good standing who are scientists-in-training and presenters of meritorious scientific papers at this year’s conference. AACR-WICR members in good standing who are graduate and medical students, residents, and postdoctoral and clinical fellows who submit abstracts are eligible to apply for this award which provides funding to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The award application deadline is **Tuesday, August 4, 2015**. Additional information, abstract submission, and application instructions are available online at [www.AACR.org/Targets15](http://www.AACR.org/Targets15).
Individuals wishing to attend the conference can register online beginning in early July at www.AACR.org/Targets15 or by returning the registration form on page 27 of this brochure. Attendee registration includes admission to all scientific sessions, poster sessions, the networking reception on November 5, conference continental breakfasts on November 6, 7, 8, and 9, and coffee breaks. All registrants agree to follow the Code of Conduct, Policies, and Procedures for the conference outlined on page 21 of this brochure.

Registration will not be processed without full payment. Government or other payment orders are not accepted. All payments must be in U.S. currency, drawn on a U.S. bank. Visa, MasterCard, and American Express are also accepted for payment. Places at the conference are on a first-come, first-served basis, according to the date of registration.

Registration Rates

Please note the two options for registering below: **Premium** (which includes access to Webcasted sessions) and **Standard** (which does not include access to Webcasted sessions).

Conference registrants will receive one complimentary drink ticket to the Networking Reception. Onsite registration will be available at the Hynes Convention Center beginning on Thursday, November 5. All registrations are for the full conference.

Spouse registration is not available in advance and may only be purchased onsite. All spouse registrations must be tied to an existing attendee record and is not available to individuals working in the cancer research field. Spouse fee includes only meals and social activities provided during the conference and does NOT admit individuals to lecture sessions. The fee for spouse registration is $175.

### Premium Package
*Includes full individual access to the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Webcast*

<table>
<thead>
<tr>
<th></th>
<th>Early Until August 24</th>
<th>Advance August 25–October 5</th>
<th>Regular/Onsite After October 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AACR and EORTC Members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active/Affiliate (Nonprofit)</td>
<td>$ 784</td>
<td>$ 989</td>
<td>$1,004</td>
</tr>
<tr>
<td>Active/Affiliate (Industry)</td>
<td>$ 994</td>
<td>$1,124</td>
<td>$1,274</td>
</tr>
<tr>
<td>Associate</td>
<td>$ 544</td>
<td>$ 694</td>
<td>$ 714</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$ 274</td>
<td>$ 299</td>
<td>$ 324</td>
</tr>
<tr>
<td><strong>Nonmembers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonprofit</td>
<td>$1,024</td>
<td>$1,224</td>
<td>$1,264</td>
</tr>
<tr>
<td>Industry</td>
<td>$1,524</td>
<td>$1,554</td>
<td>$1,624</td>
</tr>
<tr>
<td>Pre-/Postdoctoral Student(^1)</td>
<td>$ 674</td>
<td>$ 774</td>
<td>$ 829</td>
</tr>
<tr>
<td>Patient Advocate(^2)</td>
<td>$ 374</td>
<td>$ 399</td>
<td>$ 424</td>
</tr>
</tbody>
</table>

### Standard Package
*Does not include Webcast access*

<table>
<thead>
<tr>
<th></th>
<th>Early Until August 24</th>
<th>Advance August 25–October 5</th>
<th>Regular/Onsite After October 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AACR and EORTC Members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active/Affiliate (Nonprofit)</td>
<td>$ 685</td>
<td>$ 890</td>
<td>$ 905</td>
</tr>
<tr>
<td>Active/Affiliate (Industry)</td>
<td>$ 895</td>
<td>$1,025</td>
<td>$1,175</td>
</tr>
<tr>
<td>Associate</td>
<td>$ 445</td>
<td>$ 595</td>
<td>$ 615</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$ 175</td>
<td>$ 200</td>
<td>$ 225</td>
</tr>
<tr>
<td><strong>Nonmembers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonprofit</td>
<td>$ 875</td>
<td>$1,075</td>
<td>$1,115</td>
</tr>
<tr>
<td>Industry</td>
<td>$1,125</td>
<td>$1,355</td>
<td>$1,425</td>
</tr>
<tr>
<td>Pre-/Postdoctoral Student(^1)</td>
<td>$ 525</td>
<td>$ 625</td>
<td>$ 680</td>
</tr>
<tr>
<td>Patient Advocate(^2)</td>
<td>$ 225</td>
<td>$ 250</td>
<td>$ 275</td>
</tr>
</tbody>
</table>

\(^1\)Students registering onsite must show a valid student ID. Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

\(^2\)Patient advocates registering for this conference must submit a biography or a curriculum vitae and the advocate verification form to the AACR Survivor and Patient Advocacy Department at advocacy@aacr.org for verification.
Refund Policy

Requests for refunds must be made in writing and received by Friday, October 2, 2015. Refund requests may be sent by email to molecular@compusystems.com. There will be a $100 administrative fee for processing cancellations received by October 2. After October 2, no refunds can be made.

Survivor and Patient Advocate Opportunities

The AACR strongly encourages the involvement of survivors and patient advocates in this conference and is pleased to offer discounted registration rates to this group. Advocates must submit a biography or a curriculum vitae and the advocate verification form to receive the discounted rate. You can find the advocate verification form online at www.AACR.org/SurvivorsAndAdvocates. Please contact Karen Russell Mills at advocacy@aacr.org or 215-446-7104 for further information. Onsite registration at this special rate will not be available.
AACR Membership

AACR membership is available to individuals who are interested in joining the AACR and registering for this conference at discounted member rates. AACR membership offers an array of benefits, some of which include: reduced subscription rates to AACR’s eight scientific journals; abstract sponsorship privileges for AACR Annual Meetings; and networking and scientific exchange with leading researchers. The AACR is also eager to support the exchange of knowledge and research with investigators who are located in countries with emerging economies. Significantly reduced membership dues are available for these investigators.

Eligibility for Registration at AACR and EORTC Member Rates

Nonmember individuals interested in joining the AACR and registering at the early registration rate must submit membership applications no later than August 17, 2015. Individuals who are interested in joining the AACR and registering at the advance registration member rate must submit membership applications no later than September 28, 2015. Only individuals who are listed on the membership rolls as members in good standing as of October 30, 2015, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied, then the candidate will need to register in advance at the nonmember rate. Membership information and the Membership Application form can be downloaded from the AACR website at www.AACR.org/Membership. Contact the Membership Department at 215-440-9300 or membership@aacr.org with any questions.

Assistance for Attendees with Disabilities

This AACR-NCI-EORTC conference is accessible to all registrants. Attendees with special requirements for transportation, hotel accommodations, or other facilities associated with the conference should notify the AACR in advance when registering or by emailing meetings@aacr.org.

Location

The conference will be held at the John B. Hynes Veterans Memorial Convention Center (the Hynes Convention Center), located in Boston’s Back Bay area. The Center is conveniently located close to public transportation for easy access by Boston’s “T” subway system and commuter rails. In many ways, the Hynes Convention Center is a city within a city. The Hynes is connected to not one, but two major retail complexes—Prudential Center and Copley Place—that contain just about everything attendees need during the conference. Fast food, fine dining, sundries, personal services, and world-class shopping - all under one roof. Attendees can experience Boston without ever worrying about the weather! Enter the Prudential Center through the Hynes South Lobby. Turn right for the Sheraton Boston Hotel, Starbucks, dining, and business center. A left turn leads to the Prudential Center, home to an extensive food court and fine dining, as well as boutiques and shops including Saks Fifth Avenue and Lord & Taylor.

Boston attractions provide more compelling things to see and do than any other convention city in North America. From America’s history found along the Freedom Trail to world-famous museums and international cuisine. The Theater District, located only minutes from the Hynes Center, hosts Broadway plays and musicals. Jazz clubs, dance clubs, comedy clubs, and improv theaters add to the entertainment scene. And for those who consider shopping to be the ultimate entertainment, Boston offers the boutiques of Newbury Street and the shops at Quincy Market.

Career Mentoring Session

_Sponsored by Women in Cancer Research (WICR)_

Date and time to be announced

This session has been designed for graduate students, medical students and residents, and clinical and postdoctoral fellows. Following a keynote address, attendees will meet, network, and learn from many of the leading senior scientists in cancer research. Topics include careers in industry, writing a CV, careers in translational research, mentoring and supervising, and many
more. Although all conference attendees are invited to attend this session, it is geared toward early-career female investigators. Only conference registrants may participate in this session. Onsite registration will be available on a first-come, first-served basis. Seating is limited. Contact wicr@aacr.org with any questions and to learn more about Women in Cancer Research (WICR).

**Code of Conduct, Policies, and Procedures**

The AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference brings together an estimated 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology. In order for all participants to have the opportunity to gain the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the following Code of Conduct, Policies, and Procedures for Conference Participants. By registering for the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, you agree to the following terms:

- The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all participants – attendees, presenters, exhibitors, staff, vendors, etc.
- The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age, disability, ethnicity, gender, religion, or sexual orientation.
- The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with courtesy, dignity, and an open mind, being respectful when providing feedback and being open to alternate points of view.
- Children under 12 years of age are not permitted in any scientific session, poster session, the exhibit hall, or any official event taking place at this program at any time. Children cannot be left unattended or unsupervised in the convention center.
- Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants should step out of session rooms to make calls or send emails or texts as the back lighting on electronic devices is distracting to other participants.
- Use of photographic or other recording or transmission devices is strictly prohibited in all sessions (lecture and poster) without the express permission of the presenter. This is disruptive to other attendees and discourteous to speakers, who may be presenting unpublished data.
- The AACR encourages the use of social media before, during, and after this program. Please remember that the use of photographic, recording, and/or transmission devices is strictly prohibited without the express permission of the presenter.
- The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion from fact.
- A professional photographer and videographer will be on site to document conference events and activities between November 3 and November 10, 2015. Photographs and video footage are the sole property of AACR. By registering for and attending these events, attendees understand that AACR may use their likenesses for future promotional purposes. If you do not wish to be photographed, please notify the photographer and/or videographer on site.
- Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program. Participants must comply with all applicable safety guidelines related to the conference venue.
- If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the Fire Marshall has the authority to delay or terminate the conference.
- The AACR, Levy Catering, Boston Sheraton Hotel, and the Hynes Convention Center encourage responsible drinking for those drinking alcohol. Beer and wine will be offered at some official events throughout this program. Alcohol will not be served to anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.
PRESS
Members of the national and international media depend on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to provide the most up-to-date information on drug development in oncology. At this year’s conference, the American Association for Cancer Research (AACR) Communications and Public Relations Department will be conducting a press program and staffing a press room. Reporters and PIOs from medical centers who are interested in registering for the conference should contact Lauren Riley at lauren.riley@aacr.org. The AACR does not release media lists, but will make available company-sponsored press releases on abstract presentations in the press room. For more information on the Molecular Targets and Cancer Therapeutics press program contact Jeff Molter at 267-210-3965 or jeff.molter@aacr.org, Julia Gunther at 215-446-6896 or julia.gunther@aacr.org, or Lauren Riley at 215-446-7155 or lauren.riley@aacr.org.
Conference Support
The AACR Foundation welcomes support from individuals, foundations, corporations, and other organizations interested in bringing this important international education program to an estimated 3,000 conference participants from across the U.S. and the world. Our conference supporters enjoy recognition in the Molecular Targets and Cancer Therapeutics program, as well acknowledgement on the AACR website promoting the conference. Additionally, the AACR Foundation acknowledges your generous support in onsite signage throughout the conference venue. At the conference, you will enjoy interacting face to face with cancer research professionals—academics, scientists, and pharmaceutical industry representatives—to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.

For information about supporting this important conference, please contact the AACR Foundation at 215-446-7165, or:
Anizia.Karmazyn@aacr.org
Senior Director, Philanthropy and Corporate Partnerships
Jessica.Cestone@aacr.org
Director of Development

Corporate Support
Corporate supporters of the AACR-NCI-EORTC 2015 Molecular Targets and Cancer Therapeutics conference also enjoy these sponsor benefits:
- Build visibility for your organization in a competitive marketplace.
- Target highly influential decision makers and opinion leaders.
- Networking opportunities.
- Access to over 3,000 registrants.
- Complimentary scientific registrations for the conference.
- Opportunity to rent the pre- or post-registration list.

For information about distinct corporate support opportunities, please contact:
Iain.Mitchell@aacr.org
Assistant Director, Corporate Relations
215-446-7120

Professional Educational Grants
Continuing Medical Education (CME)
Ronald.Arthur@aacr.org
Senior Manager, Office of CME
215-440-9300, ext. 206
Opportunities are available to reserve an exhibit space at this conference. Over 3,000 scientists and researchers who are leading the discovery and drug development effort against cancer worldwide are expected to attend this year’s conference. Don’t miss this opportunity to further your business by meeting new contacts from industry, government, and academia. AACR Annual Meeting Exhibitors receive an additional priority point for reserving a booth at this conference. Booths are assigned on a first-come, first-served basis so be sure to get your application in before space is sold out. For further information please contact Lisa A. McGlashen, AACR Senior Exhibits Manager, at 215-440-9300 or exhibits@aacr.org.
As in previous years, the AACR will make a limited number of selected session webcasts free to all interested researchers. In addition, attendees can purchase exclusive online streaming access to the audio and slides of all scientific sessions presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.*

- Presentation slides synchronized with recorded audio presentations
- Speakers’ mouse movements captured and included in playback
- Available on compatible mobile devices and smart phones such as iPad, iPod Touch, and iPhone
- Presentations searchable by session title, presentation title, and speaker name
- Exclusive access to online content for 15 months after the conference

Purchase access to the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics by selecting the Premium Package when registering and get the lowest rates.

*Participation in the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics webcasts is left to the discretion of each speaker. As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides. Sessions will not be streamed live. Selected session webcasts will be made available free within 24 hours, and the remaining webcasts will be made available in late November. Attendees who purchased webcast access will receive login information via email at that time.
### Name and Address Information

Check here if you are a member of:  
- AACR Membership # ____________  
- EORTC  
- Nonmember  

- Dr.  
- Mr.  
- Ms.  

Last/Family Name

First Name/Middle Initial

Title/Position

Department/Division  
Institution

Street/Building or Post Office Box

City/State or Province

Zip or Postal Code/Country

Telephone  
Fax

Email

- New address. Please change my AACR mailing information.

- If you will require special accommodations, please specify:  

### Nonmember Predoctoral Student/Postdoctoral or Clinical Fellow Certification

“I certify that the above named person is presently enrolled at this University and working toward a degree or fellowship in a field related to cancer research.”

Name (Registrar, Dean, or Dept. Head)

Signature (Registrar, Dean, or Dept. Head)

Title

University

### Additional Registrant Information

**Scientific Research Focus** (check only one):  
- Basic  
- Translational  
- Clinical  
- Behavioral Science

**Primary Area of Research** (check only one):  
- Behavioral Science  
- Biochemistry and Biophysics  
- Biostatistics  
- Carcinogenesis  
- Cellular Biology  
- Chemistry  
- Clinical Investigations/Clinical Population Science Trials  
- Computational Biology  
- Endocrinology  
- Epidemiology  
- Genetics and Genomics  
- Immunology  
- Molecular Biology  
- Preclinical Pharmacology and Experimental Molecular Therapeutics

**Institution Type** (check only one):  
- Academic  
- Association/Professional/Organization  
- Cancer Center (NCI-designated)  
- Foundation/Advocacy Organization  
- Government  
- Hospital/Medical Center/Clinic  
- Industry/Private Sector  
- Nonprofit Research Organization  
- Other  
- Other Cancer Center

**Race or Ethnic Background** (check only one):  
- Caucasian  
- African American or Black  
- Hispanic or Latino  
- Asian  
- Native American  
- Alaskan Native  
- Native Hawaiian or Pacific Islander  
- Other

**Gender:**  
- Male  
- Female

Information concerning gender and ethnic background is solicited to enable the association to ensure that its programs are appropriately serving all members of the cancer research community.
Nonmember individuals interested in joining AACR and registering at the early registration rate must submit an application no later than August 17, 2015. Those individuals interested in registering at the advance registration rate must submit applications no later than September 28, 2015. Only individuals who are listed on the membership rolls as of October 30, 2015, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied then the candidate will need to register at the nonmember rate. Membership information and the application form can be downloaded from the AACR website at www.AACR.org/Membership. Contact the AACR Membership Department at 215-440-9300 or membership@aacr.org with any questions.

Refund Policy: Requests for refunds must be made in writing. There will be a $100 processing fee for cancellations until October 2, 2015. After October 2, no refunds can be given.

Financial Support for Attendance: The AACR is pleased to provide financial assistance to eligible investigators for participation in this conference, subject to availability of funding. Additional information including award application instructions are available on the Financial Support for Attendance webpage for this conference.

Method of Payment

- Check or money order enclosed, payable to American Association for Cancer Research, drawn on a U.S. bank.
- VISA
- MasterCard
- American Express

Card # Expiration Date

Print Name of Cardholder

Signature of Cardholder

Registration fees are payable in U.S. dollars only. Personal checks are acceptable if payable through a U.S. bank.

Return to:

2015 Molecular Targets
263 Warrenville Road
Suite 400
Downers Grove, IL 60515

1Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

2Patient advocates registering for this conference must submit a biography or a curriculum vitae and the advocate verification form to the AACR Survivor and Patient Advocacy Department at advocacy@aacr.org for verification.
CALL FOR ABSTRACTS  ■ Abstract Submission Deadline: August 4, 2015

2015-2016 SCIENTIFIC CONFERENCES

CRI-CIMT-EATI-AACR The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival September 16-19, 2015 • New York, NY

Chromatin and Epigenetics in Cancer Co-Chairpersons: Peter A. Jones, Sharon Y. R. Dent, and Charles W. M. Roberts September 24-27, 2015 • Atlanta, GA

Advances in Breast Cancer Research Co-Chairpersons: Matthew J. Ellis, Charles M. Perou, and Jane E. Visvader October 17-20, 2015 • Bellevue, WA

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Co-Chairpersons: Kathleen R. Cho, Douglas A. Levine, and Benjamin G. Neel October 17-20, 2015 • Orlando, FL


The Basic Science of Sarcomas Co-Chairpersons: Robert G. Maki, Angelo Paolo Dei Tos, Jonathan A. Fletcher, Lee J. Helman, and Brian A. Van Tine November 3-4, 2015 • Salt Lake City, UT

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Scientific Committee Co-Chairpersons: Levi A. Garraway, Lee J. Helman, and Jean-Charles Soria November 5-9, 2015 • Boston, MA

Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship Co-Chairpersons: Scott A. Armstrong, Charles G. Mullighan, Kevin M. Shannon, and Kimberly Stegmaier November 9-12, 2015 • Fort Lauderdale, FL

New Horizons in Cancer Research: Bringing Cancer Discoveries to Patients Shanghai 2015 Co-Chairpersons: Lewis C. Cantley and Carlos L. Arteaga November 12-15, 2015 • Shanghai, China

Tumor Metastasis Co-Chairpersons: Bruce R. Zetter, Melody A. Swartz, and Jeffrey W. Pollard November 30-December 3, 2015 • Austin, TX

CSHA/AACR Joint Meeting: Big Data, Computation, and Systems Biology in Cancer Conference Organizers: Andrea Califano, William C. Hahn, Satoru Miyano, and Xuegong Zhang December 1-5, 2015 • Suzhou, China

EORTC-NCI-EMA-AACR International Conference on Innovation and Biomarkers in Cancer Drug Development Co-Chairpersons: Denis A. Lacombe and John W. Martens December 3-4, 2015 • Brussels, Belgium

Noncoding RNAs and Cancer Co-Chairpersons: Howard Y. Chang, Jeannie T. Lee, and Joshua Mendell December 4-7, 2015 • Boston, MA

San Antonio Breast Cancer Symposium Co-Directors: Carlos L. Arteaga, Virginia Kaklamani, and C. Kent Osborne December 8-12, 2015 • San Antonio, TX

AACR-IASLC Joint Conference on Lung Cancer Chairpersons to be announced January 4-7, 2016 • San Diego, CA

The Function of Tumor Microenvironment in Cancer Progression Co-Chairpersons: Raghu Kalluri, Robert A. Weinberg, Douglas Hanahan, and Morag Park January 7-10, 2016 • San Diego, CA

Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic Co-Chairpersons: Manuel Hidaldo, Hans Clevers, S. Gail Eckhardt, and Joan Seoane February 11-14, 2016 • New Orleans, LA

10th AACR-JCA Joint Conference Co-Chairpersons: Frank McCormick and Tetsuo Noda February 16-20, 2016 • Maui, HI

AACR Precision Medicine Series: Cancer Cell Cycle–Tumor Progression and Therapeutic Response Co-Chairpersons: Julien Sage, J. Alan Diehl, and Karen E. Knudsen February 27-March 2, 2016 • Orlando, FL

AACR Annual Meeting 2016 Program Committee Chairperson: Scott Armstrong April 16-20, 2016 • New Orleans, LA
AACR-NCI-EORTC
INTERNATIONAL CONFERENCE

MOLECULAR TARGETS AND CANCER THERAPEUTICS
DISCOVERY, BIOLOGY, AND CLINICAL APPLICATIONS

November 5-9, 2015
John B. Hynes Veterans Memorial Convention Center • Boston, MA

Abstract Submission Deadline: Tuesday, August 4
Late-Breaking Abstract Submission Deadline: Thursday, September 24
Early Registration Deadline: Monday, August 24
Advance Registration Deadline: Monday, October 5

www.AACR.org